Intranasal therapeutic strategies for management of Alzheimer’s disease

References

• Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine 2011;7:521–40
   PubMed Web of Science ®Google Scholar
• Batsch NL, Mittelman MS. World Alzheimer Report 2012. Overcoming the stigma of dementia. Available from: http://www.alz.org/documents_custom/world_report_2012_final.pdf [last accessed 31 Dec 2013]
   Google Scholar
• Cummings JL, Cole G. Alzheimer disease. JAMA 2002;287:2335–8
   PubMed Web of Science ®Google Scholar
• Cole SL, Vassar R. Linking vascular disorders and Alzheimer’s disease: potential involvement of BACE1. Neurobiol Aging 2009;30:1535–44
   PubMed Web of Science ®Google Scholar
• Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease. J Control Release 2005;108:193–214
   PubMed Web of Science ®Google Scholar
• Liu G, Garrett MR, Men P, et al. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 2005;1741:246–52
   PubMed Web of Science ®Google Scholar
• Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer’s disease. Int J Biochem Cell Biol 2003;35:1505–35
   PubMed Web of Science ®Google Scholar
• Price DL, Sisodia SS. Mutant genes in familial Alzheimer’s disease and transgenic models. Annu Rev Neurosci 1998;21:479–505
   PubMed Web of Science ®Google Scholar
• Arango D, Cruts M, Torres O, et al. Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. Am J Med Genet 2001;103:138–43
   PubMed Web of Science ®Google Scholar
• Olson JM, Goddard KA, Dudek DM. The amyloid precursor protein locus and very-late-onset alzheimer disease. Am J Hum Genet 2001;69:895–9
   PubMed Web of Science ®Google Scholar
• Olson JM, Goddard KAB, Dudek DM. A second locus for very-late-onset alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet 2002;71:154–61
   PubMed Web of Science ®Google Scholar
• McIlroy SP, Vahidassr MD, Savage DA, et al. Risk of Alzheimer’s disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland. Am J Med Genet 1999;88:140–4
   PubMed Web of Science ®Google Scholar
• Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994;94:860–9
   PubMed Web of Science ®Google Scholar
• Ray B, Lahiri DK. Neuroinflammation in Alzheimer’s disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009;9:434–44
   PubMed Web of Science ®Google Scholar
• Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer’s disease. Neuromol Med 2002;1:1–31
   PubMed Web of Science ®Google Scholar
• Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha – secretase ADAM 10. Proc Natl Acad Sci USA 2001;98:5815–20
   PubMed Web of Science ®Google Scholar
• Gabuzda D, Busciglio J, Yankner BA. Inhibition of beta-amyloid production by activation of protein kinase C. J Neurochem 1993;61:2326–9
   PubMed Web of Science ®Google Scholar
• Golde TE, Younkin SG. Presenilins as therapeutic targets for the treatment of Alzheimer’s disease. Trends Mol Med 2001;7:264–9
   PubMed Web of Science ®Google Scholar
• Dingwall C. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. J Clin Inves 2001;108:1243–6
   PubMed Web of Science ®Google Scholar
• Howlett DR, Simmons DL, Dingwall C, et al. In search of an enzyme: the beta-secretase of Alzheimer’s disease is an aspartic proteinase. Trends Neurosci 2000;23:565–70
   PubMed Web of Science ®Google Scholar
• Vassar R. The beta-secretase, BACE: a prime drug target for Alzheimer’s disease. J Mol Neurosci 2001;17:157–70
   PubMed Web of Science ®Google Scholar
• Maiorini AF, Gaunt MJ, Jacobsen TM, et al. Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. J Clin Pharm Ther 2002;27:169–83
   PubMed Web of Science ®Google Scholar
• Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996;2:864–70
   PubMed Web of Science ®Google Scholar
• Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710–13
   PubMed Web of Science ®Google Scholar
• Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med 1997;3:67–72
   PubMed Web of Science ®Google Scholar
• Schraen-Maschke S, Dhaenens C-M, Delacourte A, et al. Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases. Neurobiol Dis 2004;15:449–60
   PubMed Web of Science ®Google Scholar
• Hernández F, Avila J. The role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease. FEBS Lett 2008;582:3848–54
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59
   PubMed Web of Science ®Google Scholar
• Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99:459–96
   PubMed Web of Science ®Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976;2:1403
   PubMed Web of Science ®Google Scholar
• Auld DS, Kornecook TJ, Bastianetto S, et al. Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Progress Neurobiol 2002;68:209–45
   PubMed Web of Science ®Google Scholar
• Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978;272:827–9
   PubMed Web of Science ®Google Scholar
• Sara VR, Hall K, Von Holtz H, et al. Evidence for the presence of specific receptors for insulin-like growth factors 1 (IGE-1) and 2 (IGF-2) and insulin throughout the adult human brain. Neurosci Lett 1982;34:39–44
   PubMed Web of Science ®Google Scholar
• Schiöth HB, Craft S, Brooks SJ, et al. Brain insulin signaling and Alzheimer’s disease: current evidence and future directions. Mol Neurobiol 2012;46:4–10
   PubMed Web of Science ®Google Scholar
• Agrawal R, Mishra B, Tyagi E, et al. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 2010;61:247–52
   PubMed Web of Science ®Google Scholar
• Banks WA, Kastin AJ, Pan W. Uptake and degradation of blood-borne insulin by the olfactory bulb. Peptides 1999;20:373–8
   PubMed Web of Science ®Google Scholar
• Woods SC, Seeley RJ, Baskin DG, et al. Insulin and the blood-brain barrier. Curr Pharm Des 2003;9:795–800
   PubMed Web of Science ®Google Scholar
• Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2009;36:811–22
   PubMed Web of Science ®Google Scholar
• Zhao W-Q, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease. Biochim Biophys Acta 2009;1792:482–96
   PubMed Web of Science ®Google Scholar
• Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease – is this type 3 diabetes? J Alzheimer Dis 2005;7:63–80
   PubMed Web of Science ®Google Scholar
• Messier C, Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer’s disease. Neural Plast 2005;12:311–29
   PubMedGoogle Scholar
• Vagelatos NT, Eslick GD. Type 2 diabetes as a risk factor for Alzheimers disease: the confounders, interactions and neuropathology associated with this relationship. Epidemiol Rev 2013;35:152--60
   Google Scholar
• Dominguez RO, Pagano MA, Marschoff ER, et al. Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis. Neurologia. doi:https://doi.org/10.1016/j.nrl.2013.05.006
   Google Scholar
• Mehla J, Chauhan BC, Chauhan NB. Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. J Alzheimers Dis 2013. doi: https://doi.org/10.3233/JAD-131238
   Google Scholar
• Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271:992–8
   PubMed Web of Science ®Google Scholar
• Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer’s disease. Int Psychogeriatr 2002;14:93–126
   PubMed Web of Science ®Google Scholar
• Costantino HR, Leonard AK, Brandt G, et al. Intranasal administration of acetylcholinesterase inhibitors. BMC Neuroscience 2008;9:S6
   PubMedGoogle Scholar
• Walter K, Müller M, Barkworth MF, et al. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. Br J Clin Pharmacol 1995;39:59–63
   PubMed Web of Science ®Google Scholar
• Gore AV, Liang AC, Chien YW. Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model. J Pharm Sci 1998;87:441–7
   PubMed Web of Science ®Google Scholar
• Bleich S, Römer K, Wiltfang J, et al. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003;18:S33–40
   PubMed Web of Science ®Google Scholar
• Koch HJ, Szecsey A, Haen E. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer’s and vascular dementia. Curr Pharm Des 2004;10:253–9
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001;40:959–75
   PubMed Web of Science ®Google Scholar
• Kim HG, Oh MS. Herbal medicines for the prevention and treatment of Alzheimer’s disease. Curr Pharm Des 2012;18:57–75
   PubMed Web of Science ®Google Scholar
• Li F, Gong Q, Dong H, et al. Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des 2012;18:27–33
   PubMed Web of Science ®Google Scholar
• Magrone T, Marzulli G, Jirillo E. Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products. Curr Pharm Des 2012;18:34–42
   PubMed Web of Science ®Google Scholar
• Barnham KJ, Bush AI. Metals in Alzheimer’s and Parkinson’s diseases. Curr Opin Chem Biol 2008;12:222–8
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Kudo W, et al. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 2009;455:187–90
   PubMed Web of Science ®Google Scholar
• Fawcett JR, Bordayo EZ, Jackson K, et al. Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer’s brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain Res 2002;950:10–20
   PubMed Web of Science ®Google Scholar
• Atamna H, Frey WH, Ko N. Human and rodent amyloid-β peptides differentially bind heme: relevance to the human susceptibility to Alzheimers disease. Arch Biochem Biophys 2009;487:59–65
   PubMed Web of Science ®Google Scholar
• Atamna H, Boyle K. Amyloid-β peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimers disease. Proc Natl Acad Sci USA 2006;103:3381–6
   PubMed Web of Science ®Google Scholar
• Atamna H, Frey WH II. A role of heme in Alzheimer’s disease: heme binds amyloid β and has altered metabolism. Proc Natl Acad Sci USA 2004;101:11153–8
   PubMed Web of Science ®Google Scholar
• Salloway S, Mintzer J, Weiner MF, et al. Disease-modifying therapies in Alzheimer’s disease. Alzheimers Dement 2008;4:65–79
   PubMed Web of Science ®Google Scholar
• Sahni JK, Doggui S, Ali J, et al. Neurotherapeutic applications of nanoparticles in Alzheimers disease. J Control Release 2011;152:208–31
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol 2002;59:35–40
   PubMed Web of Science ®Google Scholar
• Scherrmann J. Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol 2002;38:349–54
   PubMed Web of Science ®Google Scholar
• Jefferies WA, Brandon MR, Hunt SV, et al. Transferrin receptor on endothelium of brain capillaries. Nature 1984;312:162–3
   PubMed Web of Science ®Google Scholar
• Dick AP, Harik SI, Klip A, et al. Identification and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity. Proc Natl Acad Sci USA 1984;81:7233–7
   PubMed Web of Science ®Google Scholar
• Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 2010;31:246–54
   PubMed Web of Science ®Google Scholar
• Davis SS. Biomedical applications of nanotechnology – implications for drug targeting and gene therapy. Trends Biotechnol 1997;15:217–24
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery – possibilities, problems and solutions. J Control Release 2003;87:187–98
   PubMed Web of Science ®Google Scholar
• Frey W, Liu J, Chen X. Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 1997;4:87–92
   Web of Science ®Google Scholar
• Reger MA, Watson GS, Frey WH, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27:451–8
   PubMed Web of Science ®Google Scholar
• Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27:14239–47
   PubMed Web of Science ®Google Scholar
• Thorne RG, Hanson LR, Ross TM, et al. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008;152:785–97
   PubMed Web of Science ®Google Scholar
• Khan S, Patil K, Bobade N, et al. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target 2010;18:223–34
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011;19:468–74
   PubMed Web of Science ®Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1–18
   PubMed Web of Science ®Google Scholar
• Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997;14:259–66
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, et al. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002;28:1–13
   PubMed Web of Science ®Google Scholar
• Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001;53:3–21
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar K, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358:285–91
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Mishra AK, et al. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008;16:806–14
   PubMed Web of Science ®Google Scholar
• Sood S, Jain K, Gowthamarajan K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf B 2014;113:330–7
   PubMed Web of Science ®Google Scholar
• El-Hameed MDA, Kellaway IW. Preparation and in vitro characterisation of mucoadhesive polymeric microspheres as intra-nasal delivery systems. Eur J Pharm Biopharm 1997;44:53–60
   Web of Science ®Google Scholar
• Dalpiaz A, Scatturin A, Pavan B, et al. Poly(lactic acid) microspheres for the sustained release of antiischemic agents. Int J Pharm 2002;242:115–20
   PubMedGoogle Scholar
• Leo E, Contado C, Bortolotti F, et al. Nanoparticle formulation may affect the stabilization of an antiischemic prodrug. Int J Pharm 2006;307:103–13
   PubMedGoogle Scholar
• Jiang L, Gao L, Wang X, et al. The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm 2010;36:323–36
   PubMed Web of Science ®Google Scholar
• Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 2005;57:1666–91
   PubMed Web of Science ®Google Scholar
• Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm 1997;23:489–515
   Web of Science ®Google Scholar
• Ugwoke MI, Agu RU, Verbeke N, et al. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640–65
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654–73
   PubMed Web of Science ®Google Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614–28
   PubMed Web of Science ®Google Scholar
• Kristensson K, Olsson Y. Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol 1971;19:145–54
   PubMed Web of Science ®Google Scholar
• Hayashi M, Hirasawa T, Muraoka T, et al. Comparison of water influx and sieving coefficient in rat jejunal, rectal and nasal absorptions of antipyrine. Chem Pharm Bull 1985;33:2149–52
   PubMed Web of Science ®Google Scholar
• McMartin C, Hutchinson LE, Hyde R, et al. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987;76:535–40
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Contado C, Vighi E, et al. Preparation and characterization of particulate drug delivery systems for brain targeting. In: Ravikumar MNV, ed. Handbook of particulate drug delivery. California: American Scientific Publishers; 2008:95–119
   Google Scholar
• Chou K-J, Donovan MD. Lidocaine distribution into the CNS following nasal and arterial delivery: a comparison of local sampling and microdialysis techniques. Int J Pharm 1998;171:53–61
   Web of Science ®Google Scholar
• Sakane T, Akizuki M, Yamashita S, et al. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 1991;39:2456–8
   PubMed Web of Science ®Google Scholar
• Sakane T, Akizuki M, Taki Y, et al. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol 1995;47:379–81
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146–57
   PubMed Web of Science ®Google Scholar
• Rothen-Rutishauser BM, Schürch S, Haenni B, et al. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol 2006;40:4353–9
   PubMed Web of Science ®Google Scholar
• Rejman J, Oberle V, Zuhorn IS, et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004;377:159–69
   PubMed Web of Science ®Google Scholar
• Harush-Frenkel O, Rozentur E, Benita S, et al. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 2008;9:435–43
   PubMed Web of Science ®Google Scholar
• Jones AT. Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm 2008;354:34–8
   PubMed Web of Science ®Google Scholar
• Aspden TJ, Mason JD, Jones NS, et al. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997;86:509–13
   PubMed Web of Science ®Google Scholar
• Haffejee N, Du Plessis J, Müller DG, et al. Intranasal toxicity of selected absorption enhancers. Pharmazie 2001;56:882–8
   PubMed Web of Science ®Google Scholar
• Callens C, Adriaens E, Dierckens K, et al. Toxicological evaluation of a bioadhesive nasal powder containing a starch and Carbopol 974 P on rabbit nasal mucosa and slug mucosa. J Control Release 2001;76:81–91
   PubMed Web of Science ®Google Scholar
• Ingels KJ, Kortmann MJ, Nijziel MR, et al. Factors influencing ciliary beat measurements. Rhinology 1991;29:17–26
   PubMedGoogle Scholar
• Rusznak C, Devalia JL, Lozewicz S, et al. The assessment of nasal mucociliary clearance and the effect of drugs. Respir Med 1994;88:89–101
   PubMed Web of Science ®Google Scholar
• Romeo V, deMeireles J, Sileno A, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998;29:89–116
   PubMed Web of Science ®Google Scholar
• Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharmaceut Sci 2009;12:288–311
   PubMed Web of Science ®Google Scholar
• Frey WH, II. Method of administering neurologic agents to the brain. US Patent 5,624,898 filed 1989 and issued April 29, 1997
   Google Scholar
• Frey WH, II. Method for administering insulin to the brain. US Patent 6,313,093B1 filed 1999 and issued November 6, 2001
   Google Scholar
• Alcalá-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 2010;18:179–90
   PubMed Web of Science ®Google Scholar
• Benedict C, Frey WH, Schiöth HB, et al. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011;46:112–15
   PubMed Web of Science ®Google Scholar
• Hanson LR, Fine JM, Renner DB, et al. Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. Drug Deliv Transl Res 2012;2:160–8
   PubMedGoogle Scholar
• Renner DB, Frey WH, Hanson LR. Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. Neurosci Lett 2012;513:193–7
   PubMed Web of Science ®Google Scholar
• Freiherr J, Hallschmid M, Frey WH, et al. Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs 2013;27:505–14
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yue P, Tao T, et al. Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats. Acta Pharmacol Sin 2007;28:273–8
   PubMed Web of Science ®Google Scholar
• Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci 2007;96:473–83
   PubMed Web of Science ®Google Scholar
• Jogani VV, Shah PJ, Mishra P, et al. Nose-to-brain delivery of tacrine. J Pharm Pharmacol 2007;59:1199–205
   PubMed Web of Science ®Google Scholar
• Jogani VV, Shah PJ, Mishra P, et al. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 2008;22:116–24
   PubMed Web of Science ®Google Scholar
• Luppi B, Bigucci F, Corace G, et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 2011;44:559–65
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Frackiewicz EJ, Cutler NR. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs 2000;9:2393–402
   PubMed Web of Science ®Google Scholar
• Leonard AK, Sileno AP, MacEvilly C, et al. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. J Pharm Sci 2005;94:1736–46
   PubMed Web of Science ®Google Scholar
• Leonard AK, Sileno AP, Brandt GC, et al. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 2007;335:138–46
   PubMed Web of Science ®Google Scholar
• Arumugam K, Subramanian GS, Mallayasamy SR, et al. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008;58:287–97
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang Y, Wu K, et al. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats. Curr Alzheimer Res 2012;9:315–25
   PubMed Web of Science ®Google Scholar
• Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012;47:6–15
   PubMed Web of Science ®Google Scholar
• Hussain MA, Mollica JA. Intranasal absorption of physostigmine and arecoline. J Pharm Sci 1991;80:750–1
   PubMed Web of Science ®Google Scholar
• Dahlin M, Bjo E. Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer’s disease to rats. Int J Pharm 2001;212:267–74
   PubMedGoogle Scholar
• Hussain MA, Rakestraw D, Rowe S, et al. Nasal administration of a cognition enhancer provides improved bioavailability but not enhanced brain delivery. J Pharm Sci 1990;79:771–2
   PubMed Web of Science ®Google Scholar
• Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 2001;30:433–46
   PubMed Web of Science ®Google Scholar
• Bastianetto S, Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol Aging 2002;23:891–97
   PubMed Web of Science ®Google Scholar
• Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79:727–47
   PubMed Web of Science ®Google Scholar
• Tong-Un T, Muchimapura S, Phachonpai W, et al. Nasal administration of quercetin liposomes modulate cognitive impairment and inhibit acetylcholinesterase activity in hippocampus. Am J Neurosci 2010;1:21–7
   Google Scholar
• Phachonpai W, Wattanathorn J, Muchimapura S, et al. Neuroprotective effect of quercetin encapsulated liposomes: a novel therapeutic strategy against Alzheimer’s disease. Am J Appl Sci 2010;7:480–5
   Google Scholar
• Gowthamarajan K, Jawahar N, Wake P, et al. Development of buccal tablets for curcumin using Anacardium occidentale gum. Carbohydr Polym 2012;88:1177–83
   Web of Science ®Google Scholar
• Hamaguchi T, Ono K, Yamada M. REVIEW: curcumin and Alzheimer’s disease. CNS Neurosci Ther 2010;16:285–97
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, et al. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res 2004;75:742–50
   PubMed Web of Science ®Google Scholar
• Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem 2004;91:1199–210
   PubMed Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892–901
   PubMed Web of Science ®Google Scholar
• Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370–7
   PubMed Web of Science ®Google Scholar
• Ma Q-L, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009;29:9078–89
   PubMed Web of Science ®Google Scholar
• Piper JT, Singhal SS, Salameh MS, et al. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 1998;30:445–56
   PubMed Web of Science ®Google Scholar
• Jain K, Sood S, Gowthamarajan J. Modulation of cerebral malaria by curcumin as an adjunctive therapy. Braz J Infect Dis 2013;17:579–91
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807–18
   PubMed Web of Science ®Google Scholar
• Chen X, Zhi F, Jia X, et al. Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol 2013;65:807–16
   PubMed Web of Science ®Google Scholar
• Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer’s disease. Neurobiol Aging 1996;17:123–30
   PubMed Web of Science ®Google Scholar
• Francis G, Martinez J, Liu W, et al. Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes 2009;58:934–45
   PubMed Web of Science ®Google Scholar
• Hallschmid M, Schultes B, Marshall L, et al. Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 2004;53:2202–8
   PubMed Web of Science ®Google Scholar
• Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004;29:1326–34
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Archive Neurol 2012;69:29–38
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimer Dis 2008;13:323–31
   PubMed Web of Science ®Google Scholar
• Francis GJ, Martinez JA, Liu WQ, et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008;131:3311–34
   PubMed Web of Science ®Google Scholar
• Jauch-Chara K, Friedrich A, Rezmer A, et al. Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes 2012;61:2261–8
   PubMed Web of Science ®Google Scholar
• Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 1991;337:1304–8
   PubMed Web of Science ®Google Scholar
• Hanson LR, Roeytenberg A, Martinez AM, et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 2009;330:679–86
   PubMed Web of Science ®Google Scholar
• Fine JM, Baillargeon AM, Renner DB, et al. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice. Exp Brain Res 2012;219:381–90
   PubMed Web of Science ®Google Scholar
• Guo C, Wang T, Zheng W, et al. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging 2013;34:562–75
   PubMed Web of Science ®Google Scholar
• Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010;13:195–201
   PubMed Web of Science ®Google Scholar
• Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009;17:564–74
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154–62
   PubMed Web of Science ®Google Scholar
• Fischer W, Wictorin K, Björklund A, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329:65–8
   PubMed Web of Science ®Google Scholar
• Hefti F, Dravid A, Hartikka J. Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesions. Brain Res 1984;293:305–11
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Sang H, Yoshida K, et al. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991;30:625–36
   PubMed Web of Science ®Google Scholar
• Ruberti F, Capsoni S, Comparini A, et al. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 2000;20:2589–601
   PubMed Web of Science ®Google Scholar
• Capsoni S, Ugolini G, Comparini A, et al. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000;97:6826–31
   PubMed Web of Science ®Google Scholar
• Capsoni S, Giannotta S, Cattaneo A. Early events of Alzheimer-like neurodegeneration in anti-nerve growth factor transgenic mice. Brain Aging 2002;2:39–40
   Google Scholar
• Capsoni S, Giannotta S, Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer’s disease based on transgenic anti-nerve growth factor antibodies. Mol Cell Neurosci 2002;21:15–28
   PubMed Web of Science ®Google Scholar
• Eriksdotter Jönhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:246–57
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Blesch A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer’s disease. Prog Brain Res 2004;146:441–9
   PubMed Web of Science ®Google Scholar
• Chen X-Q, Fawcett JR, Rahman Y-E, et al. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimer Dis 1998;1:35–44
   PubMedGoogle Scholar
• Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA 2002;99:12432–7
   PubMed Web of Science ®Google Scholar
• Capsoni S, Marinelli S, Ceci M, et al. Intranasal “‘painless’” human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in App X PS1 Mice. PLoS ONE 2012;7:1–16
   Google Scholar
• Thorns V, Masliah E. Evidence for neuroprotective effects of acidic fibroblast growth factor in Alzheimer disease. J Neuropathol Exp Neurol 1999;58:296–306
   PubMed Web of Science ®Google Scholar
• Reuss B, von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 2003;313:139–57
   PubMed Web of Science ®Google Scholar
• Lou G, Zhang Q, Xiao F, et al. Intranasal administration of TAT-haFGF14-154 attenuates disease progression in mouse model of Alzheimer’s disease. Neuroscience 2012;223:225–37
   PubMed Web of Science ®Google Scholar
• Gozes I, Schächter P, Shani Y, et al. Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology 1988;47:27–31
   PubMed Web of Science ®Google Scholar
• Gozes I, Glowa J, Brenneman DE, et al. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J Mol Neurosci 1993;4:185–93
   PubMed Web of Science ®Google Scholar
• Glowa JR, Panlilio LV, Brenneman DE, et al. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res 1992;570:49–53
   PubMed Web of Science ®Google Scholar
• Gozes I, Bardea A, Reshef A, et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 1996;93:427–32
   PubMed Web of Science ®Google Scholar
• Wu H, Li J, Zhang Q, et al. A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-β25–35-treated rats following intranasal administration. Eur J Pharm Biopharm 2012;80:368–78
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997;17:1683–90
   PubMed Web of Science ®Google Scholar
• Pappolla M, Bozner P, Soto C, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998;273:7185–8
   PubMed Web of Science ®Google Scholar
• Jayachandra Babu R, Dayal PP, Pawar K, et al. Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target 2011;19:731–40
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–7
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916–19
   PubMed Web of Science ®Google Scholar
• Cattepoel S, Hanenberg M, Kulic L, et al. Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer’s disease. PLoS ONE 2011;6:e18296
   PubMedGoogle Scholar